Your cells burn food to make energy. The organelle that does the burning wears out. Here is what can meaningfully repair it, and what the supplement industry would like you to believe can.
Why This Matters
If you ask a longevity researcher which hallmark of aging they'd most want to reverse, a lot of them will say mitochondrial dysfunction. The reasoning is simple. Almost every other thing that goes wrong with an aging cell, rising inflammation, failing proteostasis, accumulating DNA damage, cellular senescence, gets worse when the cell runs low on clean energy. And the machinery that makes clean energy is the mitochondrion.
This explains why "mitochondrial health" became one of the most commercially active corners of the supplement industry. Urolithin A, MitoQ, CoQ10, NAD+ precursors, peptides like MOTS-c, "mitochondrial stacks" at 50 to 200 dollars a month. The marketing story is clean: feed your power plants, age slower.
The real story is more interesting, and more honest. Mitochondrial biology is one of the best-understood areas in all of cell biology. The interventions that actually work on human mitochondria are the ones you already know: exercise, sleep, strength training, metabolic health. The pills that work at the biochemistry level mostly haven't proved themselves at the clinical level. A few have begun to.
This is the picture I wanted laid out in one place.
What Mitochondria Actually Do
Every cell in your body (except mature red blood cells) contains mitochondria. Muscle cells and neurons pack thousands of them. Cardiac cells can be 30 percent mitochondria by volume. These organelles do three things that matter for aging:
-
Make ATP. Your cells run on adenosine triphosphate. Mitochondria produce the overwhelming majority of it by running the electron transport chain, a set of four protein complexes embedded in the inner mitochondrial membrane. Electrons from the food you ate move through these complexes. That flow pumps protons across the membrane. The protons then flow back through ATP synthase, and the rotation of that molecular turbine makes ATP. This is Peter Mitchell's chemiosmotic theory, and it's how you are powered right now.
-
Sense and handle cellular stress. Mitochondria take in calcium to buffer it, produce reactive oxygen species as a signaling molecule (and as a side effect of respiration), and release cytochrome c to trigger programmed cell death when the cell is too damaged to repair. They are the cell's power meter and its demolition switch.
-
Carry their own DNA. Every mitochondrion has a small circular genome of 37 genes, inherited almost exclusively from your mother. That DNA is more exposed to damage than nuclear DNA, and mitochondrial DNA mutations accumulate with age. This is one reason aging mitochondria work less well.
Most cells contain multiple mitochondrial populations, and healthy cells constantly cycle them: creating new mitochondria (biogenesis), fusing damaged ones with healthy ones (fusion), cutting off the damaged parts (fission), and digesting the worst copies (mitophagy). When this quality-control system works, you have a clean, efficient energy supply. When it breaks down with age, you get too many damaged mitochondria, leaking reactive oxygen species, producing less ATP, and sending "something is wrong" signals to the rest of the cell.
The Aging Story
The mitochondrial theory of aging goes back to Denham Harman in 1972. His original framing was that mitochondria generate reactive oxygen species as a byproduct of respiration, those ROS damage the mitochondria themselves, damaged mitochondria produce more ROS, and the whole system degrades in a feedback loop. That specific version of the theory has been revised substantially. ROS aren't pure villains, they have signaling roles, and antioxidant supplements have repeatedly failed to extend lifespan in humans. But the core idea, that aging mitochondria work worse and that worse mitochondria accelerate cellular aging, has survived every update.
In the 2023 update to the hallmarks of aging framework, Carlos López-Otín and colleagues kept mitochondrial dysfunction as one of the twelve core hallmarks. Their synthesis of the evidence points to several concrete changes with age:
- Fewer mitochondria per cell, especially in muscle. Skeletal muscle biopsies from older adults consistently show lower mitochondrial density than in younger adults of similar weight.
- Lower respiratory capacity in the remaining mitochondria. They run the electron transport chain less efficiently.
- More mitochondrial DNA mutations and fragmented mitochondrial networks.
- Less mitophagy, the selective autophagy process that removes damaged mitochondria. A healthy young cell clears its worst mitochondria promptly. An aging cell lets them pile up.
- More ROS leak per unit of ATP produced.
The combined effect shows up at the whole-body level as lower VO2 max, slower recovery from exercise, muscle weakness, and metabolic inflexibility. This is not a metaphor. It's the biochemistry that sits underneath the phrase "I feel older than I used to."
If you could repair this system, you would likely improve many things at once. That is the entire commercial and scientific bet behind "mitochondrial health."
What Actually Works: Exercise
Start with the intervention that has the largest and most replicated effect on human mitochondrial function. It isn't a pill.
Sustained aerobic exercise, especially at the intensity that longevity coaches now call zone 2, activates an energy-sensing kinase called AMPK. Activated AMPK phosphorylates and activates PGC-1 alpha, the transcription coactivator that López-Otín and others have called the master regulator of mitochondrial biogenesis. PGC-1 alpha turns on dozens of nuclear and mitochondrial genes that build new mitochondria. Over weeks and months, the density of mitochondria in working muscle rises substantially. High-intensity interval training produces similar signals through a different acute stimulus.
The effect sizes are big. Endurance-trained older adults can have muscle mitochondrial densities closer to sedentary twenty-somethings than to sedentary age-matched controls. That is not what a supplement trial tends to produce.
Resistance training adds a different benefit. Hypertrophy itself demands more mitochondria to supply the enlarged muscle, and recent work suggests that combined aerobic and resistance training restores not only mitochondrial density but also the fusion-fission networks that keep the mitochondrial population healthy.
A 2023 review in PNAS by Richter-Stretton and colleagues went further. In aged animals, exercise training rescued mitochondrial translation, the rate at which mitochondrial DNA is read and turned into proteins, in a PGC-1-alpha-dependent way. The aging mitochondrial genome, in other words, is at least partly readable again if you ask the cell to work.
No supplement has matched this.
The Supplements on the Market
With that context, here are the products actually being sold as "mitochondrial health" in 2026, ranked roughly by evidence quality.
Urolithin A (Mitopure). A postbiotic compound your gut makes, if it can, when you eat pomegranates, walnuts, or berries. It activates mitophagy, the cellular cleanup process that removes damaged mitochondria. Swiss biotech Amazentis isolated it, scaled it, and now sells direct supplementation as Mitopure at roughly 60 to 90 dollars a month under the Timeline brand. Received FDA "Generally Recognized As Safe" (GRAS) status in 2019.
MitoQ. A mitochondria-targeted version of the antioxidant ubiquinol. A lipophilic cation tail allows it to accumulate inside the inner mitochondrial membrane, where it can quench reactive oxygen species at their source. Roughly 60 dollars a month. The best-supported commercial claim is vascular function in older adults.
CoQ10 (ubiquinone or ubiquinol). The original mitochondrial antioxidant supplement, in the market since the 1980s. Its role in the electron transport chain is real and essential. Whether oral CoQ10 meaningfully raises mitochondrial CoQ10 in healthy adults is a much messier question. Cheap and widely available, typically 20 to 40 dollars a month.
NAD+ precursors (NR, NMN). Boost levels of the coenzyme that mitochondria need to make energy. The clinical picture is covered in depth in the NAD+ supplements piece. Short version: they raise NAD+ reliably, deliver mixed clinical benefit.
MOTS-c. A 16-amino-acid peptide encoded by mitochondrial DNA itself. Exercise causes a roughly 12-fold increase in MOTS-c in skeletal muscle. In mouse work by Reynolds et al. in Nature Communications (2021), MOTS-c injection improved insulin sensitivity and exercise capacity in aged mice. MOTS-c is not an approved supplement, is only legally available through research suppliers, and was added to the World Anti-Doping Agency prohibited list in 2024.
Stacks and cocktails. "Mitochondrial formulas" combining several of the above with magnesium, B vitamins, creatine, L-carnitine, and alpha-lipoic acid. These are marketing products, not independent interventions. The evidence belongs to the individual ingredients, most of which is weak outside of specific clinical populations.
What the Human Trials Actually Show
Urolithin A, the most interesting new entrant.
Two complementary 2022 trials shaped the current picture for Mitopure.
Singh et al., published in Cell Reports Medicine in 2022 (the ATLAS trial), enrolled 88 untrained, overweight middle-aged adults who were randomized to placebo, 500 mg, or 1,000 mg of urolithin A daily for four months. Hamstring muscle strength improved by roughly 12 percent at both doses (p equals 0.027 and 0.029 versus placebo). Aerobic endurance (VO2 peak) and 6-minute walk distance improved as well. Plasma acylcarnitines, a marker of impaired fatty-acid oxidation in dysfunctional mitochondria, went down. The primary endpoint of the trial was peak power output, which did not show a statistically significant improvement. The biomarker and secondary endpoints were the positive story.
Liu et al., published in JAMA Network Open in 2022, tested 1,000 mg of urolithin A daily for four months in 66 older adults aged 65 to 90. Muscle endurance in both hand and leg muscles improved significantly versus placebo. The supplement was safe and well tolerated in this older population.
These are better results than most of the NAD+ precursor literature in comparable populations. They are still single-sponsor trials with primary endpoints that were surrogates or endurance measures, and the ATLAS trial missed its pre-specified primary endpoint. But the consistency across muscle strength, endurance, and mitochondrial biomarkers is real.
The 2025 MitoImmune trial, published in Nature Aging, is the follow-up. Fifty healthy middle-aged adults took 1,000 mg of Mitopure or placebo for four weeks. The treatment group showed improved function of specific immune cell subsets and lower levels of several inflammatory markers. The effects were modest but statistically meaningful in a short trial.
The Enduro trial in Sports Medicine, also 2024 to 2025, tested Mitopure in 42 elite male distance runners over four weeks. Exercise-induced muscle strain markers were lower, perceived exertion during training sessions dropped, and protein markers of mitochondrial function were elevated. This is the first athletic-performance signal for an oral mitochondrial supplement.
The bigger trials are coming. A 650-participant brain-health study and a cancer-immunotherapy adjunct trial are both expected to report in the next two years. Until they do, Mitopure is the most interesting "emerging" mitochondrial supplement, but it has not been shown to meaningfully change hard clinical outcomes in anyone without a specific indication.
MitoQ, the vascular story.
Rossman et al., published in Hypertension in 2018, is the reference trial for mitochondria-targeted antioxidants. Twenty healthy older adults (ages 60 to 79) took 20 mg of MitoQ or placebo daily for six weeks in a crossover design. Brachial artery flow-mediated dilation, the gold-standard noninvasive measure of endothelial function, was 42 percent higher after MitoQ than after placebo. Aortic stiffness improved in participants who started out with elevated stiffness. Oxidized LDL, a marker of systemic oxidative stress, dropped.
This is a clean, well-designed, mechanistically coherent trial. Endothelial function is a meaningful vascular aging marker with independent links to cardiovascular events. The main caveats are the small sample, the single site, and the surrogate endpoints. A follow-up trial expanding the vascular-outcomes work is underway at the University of Colorado Boulder.
CoQ10, the older story.
CoQ10 has been studied in dozens of populations, and the evidence is messy. Two clear positives stand out. The Q-SYMBIO trial of CoQ10 in heart failure patients, published in 2014, showed reduced major adverse cardiovascular events and mortality over two years at 300 mg daily. The KiSel-10 trial, a Swedish study combining CoQ10 and selenium in healthy older adults, reported lower cardiovascular mortality over four years and in long-term follow-up. In healthy adults without a diagnosed condition, most CoQ10 trials show little to no clinical benefit on outcomes, though measurable effects on exercise-related oxidative stress markers do appear.
CoQ10 is the mitochondrial supplement with the longest track record and the weakest hype cycle. That tells you something about what happens to a longevity claim once it's been studied for four decades.
NAD+ precursors.
Already covered in detail in NAD+ supplements: what the evidence actually shows. Summary for the mitochondrial angle: NR and NMN raise blood NAD+ reliably. Whether they reach mitochondrial NAD+ in meaningful amounts in human tissue, and whether that drives mitochondrial benefit for healthy adults, is still unresolved.
The meta picture.
A 2024 review in Aging Cell by Li et al. on interactions between mitochondrial dysfunction and other aging hallmarks made the honest point: targeting mitochondria with a single intervention is unlikely to deliver dramatic benefit because mitochondrial dysfunction is tangled up with almost every other aging process. The interventions that move the needle in humans tend to be the ones that hit multiple hallmarks at once. Exercise is the clearest example. Caloric restriction and several of its mimetics are another. A purified small molecule that only affects mitophagy or only affects NAD+ or only affects ROS may simply not be enough to overcome the whole aged system.
The "Mitochondrial Producer" Problem
One detail worth knowing about urolithin A specifically. Your gut produces it from ellagitannins (the fibrous polyphenols in pomegranate, walnuts, berries, and muscadine grapes) via specific gut bacteria, primarily Gordonibacter species. The catch: only about 40 percent of adults have a microbiome that meaningfully produces UA after eating these foods. Twelve percent of people have circulating UA at baseline. For the majority, eating pomegranate does not equal getting urolithin A.
This is the commercial rationale for direct supplementation with Mitopure. If you aren't a "UA producer," dietary ellagitannins don't reach your cells as urolithin A. Whether you want to correct this with a supplement or simply eat the whole foods and get the other benefits (fiber, polyphenols, antioxidant vitamins) is a reasonable question. The honest answer is that there's no evidence your mitochondria specifically need urolithin A from a pill if you already exercise, sleep well, and eat the foods that give your cells the raw materials for their own repair processes.
Safety: What We Know and What We Don't
Short-term safety data for the main commercial mitochondrial supplements looks clean.
Urolithin A has FDA GRAS status and passed toxicology studies in animals. Human trials up to four months have reported no significant adverse events at doses up to 1,000 mg daily. Long-term safety (beyond one year of continuous use) is unknown.
MitoQ at 20 mg daily has been safe in trials up to six weeks, with mild GI discomfort reported occasionally. Longer-duration safety data is limited.
CoQ10 has the longest safety record of any of these. Chronic use up to 1,200 mg daily has been well tolerated in large populations, though most adults use 100 to 300 mg.
MOTS-c has no approved human safety profile. Using it recreationally as an injectable peptide is a significant risk and is banned in competitive sport.
The broader, theoretical concern across mitochondrial-targeted supplements is the same one that applies to antioxidant supplements generally: if you blunt mitochondrial ROS signals chronically, you might also blunt the beneficial adaptations that exercise and metabolic stress normally drive. Several studies have shown that high-dose vitamin C and vitamin E taken around exercise can reduce the adaptive benefit of training. Whether the same applies to MitoQ or urolithin A is open. It's a reason not to stack these aggressively with training.
Where the Evidence Actually Stands
| Evidence Type | Mitochondrial Health Status |
|---|---|
| Do mitochondria decline with age? | Yes. Well established. |
| Does exercise improve mitochondrial function in humans? | Yes. Large, replicated effects. |
| Do mitochondrial supplements raise biomarkers of mitochondrial health? | Yes for several (urolithin A, MitoQ, NAD+ precursors). |
| Do they improve clinical or functional outcomes in healthy adults? | Limited. Urolithin A in sedentary elderly is the clearest positive so far. |
| Have they extended human lifespan in any trial? | No. |
| Long-term safety (beyond one to two years)? | Mostly unknown. |
| Is targeting mitochondria alone likely to dramatically slow aging? | Probably not. Mitochondrial dysfunction is tangled with every other hallmark. |
The mitochondrial-health story is one where the biology is real, the decline is real, the core intervention (exercise) works robustly, and the commercial supplement story is a mix of emerging good evidence (urolithin A, MitoQ for vascular function), older mixed evidence (CoQ10), and overreach. A healthy adult who wants to do something concrete for their mitochondria should train in zone 2 two or three times a week, lift weights twice a week, sleep seven to nine hours, and eat enough protein. The supplement layer is optional, and its upside is modest.
The Bottom Line
If a friend asked me how to think about mitochondrial health, I'd say this.
The organelle is real. The decline is real. And the interventions with the largest human effect sizes are almost all lifestyle, not pharmaceutical. Exercise hits AMPK and PGC-1 alpha more powerfully than any pill on the market. Sleep gives your cells the window to run mitophagy. Protein intake and creatine supply the substrates your muscle needs to build new mitochondria in the first place.
On top of that foundation, the most promising emerging supplement is urolithin A, with the best positive human trial in sedentary older adults. MitoQ has a clean vascular signal. CoQ10 is cheap and reasonable in specific cardiovascular contexts. NAD+ precursors are biochemically active with mixed clinical results. MOTS-c is not yet a consumer intervention and should not be treated as one.
What is not true is that any of these supplements has been shown to extend lifespan or meaningfully slow biological aging in healthy humans. Marketing language that implies otherwise is running ahead of the data.
If you are going to spend money in this area, spend it on a good pair of running shoes and a weight bench first, and on a mitochondrial supplement last. That ordering matches the evidence.
Frequently Asked Questions
What is mitochondrial health? Mitochondrial health refers to the number, quality, and function of the mitochondria inside your cells. Healthy mitochondria efficiently convert food into ATP, produce fewer reactive oxygen species per unit of energy made, maintain intact inner membranes with well-formed cristae, and are constantly renewed through a balanced cycle of biogenesis, fusion, fission, and mitophagy. Mitochondrial dysfunction is one of the twelve hallmarks of aging identified in the 2023 López-Otín framework.
How does mitochondrial health change with age? Mitochondrial density in muscle drops, respiratory capacity in the remaining mitochondria falls, mitochondrial DNA accumulates mutations, mitochondrial networks fragment, and mitophagy slows down so that damaged mitochondria pile up. The whole-body consequences include lower VO2 max, slower recovery, muscle weakness, and reduced metabolic flexibility.
What foods support mitochondrial health? Foods rich in polyphenols and ellagitannins (pomegranate, walnuts, berries, especially pomegranate and muscadine grapes) provide the raw material your gut bacteria convert into urolithin A, when your microbiome is able to do so. Fatty fish, olive oil, and green vegetables provide omega-3 fats and B vitamins that mitochondria need. High-protein foods supply the amino acids needed to build new mitochondrial proteins. No single food is a "mitochondrial booster" on its own.
Does exercise actually build new mitochondria? Yes, and this is the best-supported intervention in the entire mitochondrial-health field. Sustained aerobic exercise, especially in zone 2, activates AMPK, which activates PGC-1 alpha, which drives mitochondrial biogenesis. Over weeks and months of consistent training, mitochondrial density in working muscle rises substantially. Resistance training adds further benefits for mitochondrial network quality.
Do urolithin A supplements like Mitopure work? Two 2022 trials show the clearest signal. Singh et al. in Cell Reports Medicine (ATLAS trial, 88 middle-aged adults, 4 months) found a roughly 12 percent improvement in hamstring muscle strength at 500 and 1,000 mg doses, along with improved VO2 peak and 6-minute walk distance, though the prespecified primary endpoint (peak power output) was not met. Liu et al. in JAMA Network Open (66 older adults aged 65 to 90, 4 months) found improved muscle endurance at 1,000 mg. A 2025 immune-health trial and a 2024 elite-athlete trial showed smaller, short-term benefits. Urolithin A has FDA GRAS status. Large outcome trials have not yet reported.
What about MitoQ? MitoQ is a mitochondria-targeted antioxidant. In a 2018 randomized crossover trial in healthy older adults, 20 mg daily for six weeks improved brachial artery flow-mediated dilation by 42 percent versus placebo, a meaningful vascular-aging signal. Sample size was small and the trial used surrogate endpoints. Larger outcome trials are in progress.
Is CoQ10 worth taking? CoQ10 has the longest safety record of any mitochondrial supplement. Two older RCTs (Q-SYMBIO in heart failure, KiSel-10 in older Swedish adults with selenium) showed cardiovascular benefits. In otherwise healthy adults without a diagnosed condition, most CoQ10 trials show modest effects on oxidative stress markers and little change in clinical outcomes. It's cheap, safe, and reasonable for specific cardiovascular indications.
Are mitochondrial supplements safe? Short-term safety (up to 6 months) for urolithin A, MitoQ, and CoQ10 is well established. Long-term safety beyond one to two years is largely unknown. A theoretical concern with mitochondrial-targeted antioxidants is that blunting ROS signals may blunt the adaptive benefits of exercise, so stacking these aggressively with training is not well justified.
Should I take a mitochondrial supplement? Only after you are already training consistently, sleeping well, and eating enough protein. Without that foundation, no pill in this category will matter much. With it, urolithin A has the strongest emerging signal, MitoQ has the cleanest vascular signal, and CoQ10 is reasonable in cardiovascular contexts. All of them remain "emerging" evidence in 2026.
Sources
-
López-Otín, C., Blasco, M.A., Partridge, L., Serrano, M., and Kroemer, G. (2023). "Hallmarks of aging: An expanding universe." Cell. Link
-
Liu, S., et al. (2022). "Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial." JAMA Network Open. Link
-
Singh, A., et al. (2022). "Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults." Cell Reports Medicine. Link
-
Denk, D., et al. (2025). "Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial." Nature Aging. Link
-
Rossman, M.J., et al. (2018). "Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults." Hypertension. Link
-
Reynolds, J.C., et al. (2021). "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nature Communications. Link
-
Li, X., et al. (2024). "Interactions between mitochondrial dysfunction and other hallmarks of aging: Paving a path toward interventions that promote healthy old age." Aging Cell. Link
-
Romani, M., et al. (2021). "Direct supplementation with Urolithin A overcomes limitations of dietary exposure and gut microbiome variability in healthy adults to achieve consistent levels across the population." European Journal of Clinical Nutrition. Link
-
Islam, H., et al. (2020). "An acute bout of high-intensity interval training increases the nuclear abundance of PGC-1 alpha and activates mitochondrial biogenesis in human skeletal muscle." American Journal of Physiology: Regulatory, Integrative and Comparative Physiology. Link
-
Mortensen, S.A., et al. (2014). "The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial." JACC: Heart Failure. Link
-
Alehagen, U., et al. (2013). "Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens." International Journal of Cardiology. Link
-
Harman, D. (1972). "The biologic clock: the mitochondria?" Journal of the American Geriatrics Society. Historical origin of the mitochondrial theory of aging.
-
Mitchell, P. (1961). "Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism." Nature. Original statement of chemiosmotic theory.
-
Nobel Prize in Chemistry. (1978). "Peter D. Mitchell – Facts." Link
-
Ballesteros-Álvarez, J., and Andersen, J.K. (2021). "mTORC2: The other mTOR in autophagy regulation." Aging Cell. Mitophagy mechanism context. Link
Funding Transparency
LSD is editorially independent. We receive no funding from pharmaceutical, supplement, or longevity companies. Here is what we found about the funding relationships behind the research cited above:
- Sources 2, 3, 4, 8 (urolithin A trials) were funded by Amazentis SA, the Swiss biotech that manufactures and sells Mitopure (urolithin A). Several co-authors on these papers are Amazentis employees. This is disclosed in the publications. The trials still represent the best available human data on urolithin A, but the commercial relationship should be weighed.
- Source 5 (MitoQ vascular trial) was funded by the National Institutes of Health (R01 AG047784) and did not receive commercial funding from MitoQ Ltd. Study material was sourced independently.
- Source 6 (MOTS-c) was funded by the NIH and the Ellison Medical Foundation. The senior author, Pinchas Cohen, co-founded CohBar, a company developing mitochondrial peptide therapeutics.
- Source 10 (Q-SYMBIO) was an investigator-initiated trial supported in part by Pharma Nord, which sells CoQ10 supplements. This is disclosed.
- Source 11 (KiSel-10) received support from Pharma Nord for trial material supply. The analysis and conclusions were investigator-led.
- Sources 1, 7 (López-Otín hallmarks papers; Aging Cell review) are academic reviews. No direct commercial funding for the review writing. Individual authors disclose consulting relationships with various biotech firms.
The pattern here is typical for emerging nutraceutical research: the most interesting recent human trials (urolithin A) have been funded by the companies that make the products. This is not automatically disqualifying, but it means a genuinely independent confirmation in a larger, multi-site trial will matter more than any single industry-funded result. We'll watch for that.
Related Reading
- NAD+ Supplements: What the Evidence Actually Shows - The companion piece on the coenzyme that your mitochondria also depend on
- Hallmarks of Aging - The twelve-hallmark framework in which mitochondrial dysfunction sits
- Exercise and Longevity: Zone 2 Training - The intervention that outperforms every pill in this category
- VO2 Max: First Principles - The whole-body measure that correlates most directly with mitochondrial capacity
- Nutrition and Longevity - Dietary foundations that supply mitochondria with what they need
- Sleep and Aging - The nightly window during which mitophagy and cellular cleanup actually happen
- Metabolic Health Fundamentals - The upstream context for how cells demand, and produce, energy
Written with the help of AI tools, shaped and verified by humans who care about getting this right.
This is not medical advice. Consult your healthcare provider before starting any supplement, especially if you have an existing medical condition or are taking other medications.